Immix Biopharma Highlights NXC-201 Progress at Conference

Immix Biopharma shares rose 4.9% to trade at $12.50 compared to a previous close of $11.92 as of September 17, 2026, as management highlighted clinical milestones and an extended cash runway for its lead CAR T therapy, NXC-201, during the Morgan Stanley 24th Annual Global Healthcare Conference. The company outlined timelines for upcoming trial data and regulatory filings for its treatment targeting AL amyloidosis, a rare protein-folding disorder.

"We were founded on the idea that patients should not have to endure months of suffering without hope," said Chief Executive Akhmed Rachman in a statement regarding the corporate strategy.

Clinical Timelines and Regulatory Path for NXC-201

Immix Biopharma plans to report top-line data for its 45-patient registrational study, known as NEXICART-2, in late September 2024. Following the data readout, the biotechnology firm expects to file its biologics license application in March 2025.

Management reported that current cash on hand provides a financial runway through mid-2028. This funding covers the ongoing registrational trial, biologics license application preparation, commercial launch readiness, and a planned frontline Phase III study.

Expanding Cell Therapy Beyond Oncology

During the presentation, leadership positioned NXC-201 as an effort to make advanced cell therapy practical outside traditional oncology settings, emphasizing the therapy's shorter cytokine release syndrome profile.

"It's a liberating therapy," said Gabriel, co-founder of Immix Biopharma, citing feedback from principal investigators involved in the clinical evaluation of the drug.

AL amyloidosis occurs when misfolded proteins build up in organs, most frequently the heart and kidneys. Traditional treatments involve chemotherapy and stem cell transplants, which carry significant toxicity profiles and lengthy recovery periods, making targeted immunotherapies an area of active clinical investigation.

Market Valuation and Financial Position

Trading on the public markets under the ticker IMMX, the company's recent share price movement reflects investor focus on near-term regulatory catalysts. According to Finnhub market data, the 4.87% gain brought the stock to $12.50 ahead of the company's scheduled clinical readouts.